Vakaramoko "Karam" Diaby

Vakaramoko "Karam" Diaby,

Adjunct Professor

Department: Pharmaceutical Outcomes & Policy
Business Phone: (352) 273-6268
Business Email: v.diaby@ufl.edu

Teaching Profile

Courses Taught
2017-2023
PHA7979 Advanced Research
2019-2023
PHA7980 Research for Doctoral Dissertation
2019-2024
PHA6935 Selected Topics in Pharmacy
2018,2020-2021
PHA6910 Supervised Research
2020-2021
PHA6806 Pharmacoeconomic Modeling
2018-2021
PHA5876C Pt Care 8 Complex Pts
2021
PHA5787 Pharmacotherapy 5
2018-2019,2021
PHA5787C Pt Care 5: Endo
2018-2019,2021
PHA5784C Pt Care 4: GI and Renal
2018-2021
PHA6265 Introduction to Pharmaceutical Outcomes and Policy I
2021
PHA6937 Topics in Pharmaceutical Administration
2021
PHA6940 Supervised Teaching
2018,2020-2021
PHA6971 Research for Master’s Thesis
2021
PHA6936 Advanced Topics in Pharmaceutical Sciences
2018-2020
PHA6286 Pharmaceutical Microeconomics
2018-2020
PHA6287 Pharmaceutical Health Economics

Research Profile

Open Researcher and Contributor ID (ORCID)

Publications

2024
Association between trajectories of adherence to endocrine therapy and risk of treated breast cancer recurrence among US nonmetastatic breast cancer survivors.
British journal of cancer. 130(12):1943-1950 [DOI] 10.1038/s41416-024-02680-0. [PMID] 38637603.
2024
Association between trajectories of prescription opioid use and risk of opioid use disorder and overdose among US nonmetastatic breast cancer survivors.
Breast cancer research and treatment. 204(3):561-577 [DOI] 10.1007/s10549-023-07205-6. [PMID] 38191684.
2024
Economic Burden of Medically Attended Respiratory Syncytial Virus Infections Among Privately Insured Children Under 5 Years of Age in the USA.
Influenza and other respiratory viruses. 18(7) [DOI] 10.1111/irv.13347. [PMID] 38951044.
2024
Estimating and Rewarding the Value of Healthcare Interventions Beyond the Healthcare Sector: A Conceptual Framework.
PharmacoEconomics. 42(Suppl 2):211-224 [DOI] 10.1007/s40273-024-01392-w. [PMID] 38758291.
2023
Application of Machine Learning Algorithms to Predict Uncontrolled Diabetes Using the All of Us Research Program Data.
Healthcare (Basel, Switzerland). 11(8) [DOI] 10.3390/healthcare11081138. [PMID] 37107973.
2023
Development and validation of a tool to predict high-need, high-cost patients hospitalised with ischaemic heart disease.
BMJ open. 13(9) [DOI] 10.1136/bmjopen-2023-073485. [PMID] 37751949.
2023
Economic Impact of Universal Hepatitis C Virus Testing for Middle-Aged Adults Who Inject Drugs.
American journal of preventive medicine. 64(1):96-104 [DOI] 10.1016/j.amepre.2022.08.016. [PMID] 36257884.
2023
Oral fluoroquinolones and risk of aortic aneurysm or dissection: A nationwide population-based propensity score-matched cohort study.
Pharmacotherapy. 43(9):883-893 [DOI] 10.1002/phar.2841. [PMID] 37381584.
2023
Predictors of 30-day readmission, mortality, and length of stay for hospitalized U.S. patients with Alzheimer’s and related dementias from 2010 to 2015.
Expert review of pharmacoeconomics & outcomes research. 23(5):555-559 [DOI] 10.1080/14737167.2023.2195628. [PMID] 36974630.
2023
Trends, characteristics, race, and ethnicity associated with nonadherence to antidepressants among breast cancer survivors with depression.
Journal of managed care & specialty pharmacy. 29(4):431-445 [DOI] 10.18553/jmcp.2023.29.4.431. [PMID] 36989452.
2022
An Umbrella Review of the Cost Effectiveness of Human Papillomavirus Vaccines.
Clinical drug investigation. 42(5):377-390 [DOI] 10.1007/s40261-022-01155-5. [PMID] 35488964.
2022
Comparative cost-effectiveness of radiotherapy among older women with hormone receptor positive early-stage breast cancer.
Expert review of pharmacoeconomics & outcomes research. 22(5):735-741 [DOI] 10.1080/14737167.2022.2044309. [PMID] 35189767.
2022
Cost Effectiveness of Dapagliflozin Added to Standard of Care for the Management of Diabetic Nephropathy in the USA.
Clinical drug investigation. 42(6):501-511 [DOI] 10.1007/s40261-022-01160-8. [PMID] 35614298.
2022
Effects, trends, costs associated with readmission in early-aged patients with suicidal ideation.
Expert review of pharmacoeconomics & outcomes research. 22(2):247-258 [DOI] 10.1080/14737167.2021.1914593. [PMID] 33827359.
2022
Health Care Utilization and Costs Associated With Systemic First-Line Metastatic Melanoma Therapies in the United States.
JCO oncology practice. 18(1):e163-e174 [DOI] 10.1200/OP.21.00140. [PMID] 34228489.
2022
Predictors of 30-day readmission and hospitalization costs of patients with hepatic encephalopathy in the US from 2010 to 2014.
Expert review of pharmacoeconomics & outcomes research. 22(3):409-415 [DOI] 10.1080/14737167.2021.1927717. [PMID] 33985399.
2022
Real-world economic evaluation of prospective rapid whole-genome sequencing compared to a matched retrospective cohort of critically ill pediatric patients in the United States.
The pharmacogenomics journal. 22(4):223-229 [DOI] 10.1038/s41397-022-00277-5. [PMID] 35436997.
2022
RSV testing practice and positivity by patient demographics in the United States: integrated analyses of MarketScan and NREVSS databases.
BMC infectious diseases. 22(1) [DOI] 10.1186/s12879-022-07659-x. [PMID] 35941563.
2021
A pharmacovigilance study to quantify the strength of association between the combination of antimalarial drugs and azithromycin and cardiac arrhythmias: implications for the treatment of COVID-19.
Expert review of pharmacoeconomics & outcomes research. 21(1):159-168 [DOI] 10.1080/14737167.2021.1851600. [PMID] 33186061.
2021
Cascade of Hepatitis C Virus Care Among Patients With Substance Use Disorders.
American journal of preventive medicine. 61(4):576-584 [DOI] 10.1016/j.amepre.2021.04.013. [PMID] 34210584.
2021
Cost-effectiveness and drug wastage of immunotherapeutic agents for hematologic malignancies: a systematic review.
Expert review of pharmacoeconomics & outcomes research. 21(5):923-941 [DOI] 10.1080/14737167.2021.1913056. [PMID] 33934691.
2021
Cost-effectiveness of treatments for HER2-positive metastatic breast cancer and associated metastases: an overview of systematic reviews.
Expert review of pharmacoeconomics & outcomes research. 21(3):353-364 [DOI] 10.1080/14737167.2021.1848553. [PMID] 33213205.
2021
Evaluation of statin discontinuation stratified by primary versus secondary prevention following bariatric surgery: a retrospective cohort study.
Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery. 17(5):939-946 [DOI] 10.1016/j.soard.2021.01.025. [PMID] 33648887.
2021
Health care utilization and costs associated with direct-acting antivirals for patients with substance use disorders and chronic hepatitis C.
Journal of managed care & specialty pharmacy. 27(10):1388-1402 [DOI] 10.18553/jmcp.2021.27.10.1388. [PMID] 34595949.
2021
Identification of risk factors of 30-day readmission and 180-day in-hospital mortality, and its corresponding relative importance in patients with Ischemic heart disease: a machine learning approach.
Expert review of pharmacoeconomics & outcomes research. 21(5):1043-1048 [DOI] 10.1080/14737167.2021.1842200. [PMID] 33131344.
2021
Incorporating health equity into value assessment: frameworks, promising alternatives, and future directions
Journal Of Managed Care & Specialty Pharmacy. S24-S31 [DOI] 10.18553/jmcp.2021.27.9-a.s24. [PMID] 34534006.
2021
Incorporating health equity into value assessment: frameworks, promising alternatives, and future directions.
Journal of managed care & specialty pharmacy. 27(9-a Suppl):S22-S29 [DOI] 10.18553/jmcp.2021.27.9-a.s22. [PMID] 34579542.
2021
Prevalence and effects of suicidal ideation diagnosis code position in claims on readmission rate estimates.
Research in social & administrative pharmacy : RSAP. 17(6):1174-1180 [DOI] 10.1016/j.sapharm.2020.09.003. [PMID] 32928656.
2020
A cost-effectiveness analysis of trastuzumab-containing treatment sequences for HER-2 positive metastatic breast cancer patients in Taiwan.
Breast (Edinburgh, Scotland). 49:141-148 [DOI] 10.1016/j.breast.2019.11.012. [PMID] 31805500.
2020
A quantitative analysis of the effect of continuity of care on 30-day readmission and in-hospital mortality among patients with acute ischemic stroke.
Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association. 29(9) [DOI] 10.1016/j.jstrokecerebrovasdis.2020.105053. [PMID] 32807459.
2020
Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer.
Journal of managed care & specialty pharmacy. 26(2) [DOI] 10.18553/jmcp.2020.26.2.221. [PMID] 32011959.
2020
Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data.
The pharmacogenomics journal. 20(5):724-735 [DOI] 10.1038/s41397-020-0162-5. [PMID] 32042096.
2020
Cost-Effectiveness of Subsequent Whole-Brain Radiotherapy or Hippocampal-Avoidant Whole-Brain Radiotherapy Versus Stereotactic Radiosurgery or Surgery Alone for Treatment of Melanoma Brain Metastases.
Applied health economics and health policy. 18(5):679-687 [DOI] 10.1007/s40258-020-00560-1. [PMID] 32157631.
2020
Dataset used in the economic evaluation trastuzumab-based regimens for HER-2 positive metastatic breast cancer patients in the Taiwanese healthcare setting.
Data in brief. 29 [DOI] 10.1016/j.dib.2020.105194. [PMID] 32071975.
2020
Examining factors associated with adherence to hormonal therapy in breast cancer patients.
Research in social & administrative pharmacy : RSAP. 16(4):574-582 [DOI] 10.1016/j.sapharm.2019.08.005. [PMID] 31473108.
2020
In our war against the opioid epidemic, could ‘weed’ be a winner?
Expert review of pharmacoeconomics & outcomes research. 20(5):423-429 [DOI] 10.1080/14737167.2020.1807944. [PMID] 32799573.
2020
Predicting Cost-Effectiveness of Generic vs. Brand Dabigatran Using Pharmacometric Estimates Among Patients with Atrial Fibrillation in the United States.
Clinical and translational science. 13(2):352-361 [DOI] 10.1111/cts.12719. [PMID] 32053288.
2020
Real-World Clinical and Economic Outcomes Associated with Palbociclib for HR-Positive/HER-2 Negative Metastatic Breast Cancer: A commentary
Journal Of Managed Care & Specialty Pharmacy.
2020
Real-World Clinical and Economic Outcomes Associated with Palbociclib for HR-Positive/HER2 Negative Metastatic Breast Cancer: A Commentary.
Journal of managed care & specialty pharmacy. 26(7):826-831 [DOI] 10.18553/jmcp.2020.26.7.826. [PMID] 32584682.
2020
Self-assessed life expectancy among older adults in Côte d’Ivoire.
BMC public health. 20(1) [DOI] 10.1186/s12889-020-09034-4. [PMID] 32539697.
2020
Timing, Costs, and Survival Outcome of Specialty Palliative Care in Medicare Beneficiaries With Metastatic Non-Small-Cell Lung Cancer.
JCO oncology practice. 16(12):e1532-e1542 [DOI] 10.1200/OP.20.00298. [PMID] 33006914.
2020
Using time series analysis to forecast the health-related quality of life of post-menopausal women with non-metastatic ER+ breast cancer: A tutorial and case study.
Research in social & administrative pharmacy : RSAP. 16(8):1095-1099 [DOI] 10.1016/j.sapharm.2019.11.009. [PMID] 31753693.
2019
Comparative effectiveness of radiotherapy for early-stage hormone receptor-positive breast cancer in elderly women using real-world data.
Cancer medicine. 8(1):117-127 [DOI] 10.1002/cam4.1904. [PMID] 30548840.
2019
Multicriteria Decision Analysis to Support Health Technology Assessment Agencies: Benefits, Limitations, and the Way Forward.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 22(11):1283-1288 [DOI] 10.1016/j.jval.2019.06.014. [PMID] 31708065.
2019
Value Assessment Frameworks in the United States: A Call for Patient Engagement.
PharmacoEconomics – open. 3(1):1-3 [DOI] 10.1007/s41669-018-0094-z. [PMID] 30182346.
2018
An Evaluation of the Clinical Therapeutic Effect of Lixisenatide in Type 2 Diabetes Patients: A Systematic Literature Review.
Current diabetes reviews. 14(4):363-375 [DOI] 10.2174/1573399813666170724113240. [PMID] 28738763.
2018
An Evaluation of the Cost-effectiveness of Comprehensive MTM Integrated with Point-of-Care Phenotypic and Genetic Testing for U.S. Elderly Patients After Percutaneous Coronary Intervention.
Journal of managed care & specialty pharmacy. 24(2):142-152 [DOI] 10.18553/jmcp.2018.24.2.142. [PMID] 29384027.
2018
Longitudinal Effects of Adjuvant Endocrine Therapy on the Quality of Life of Post-menopausal Women with Non-metastatic ER+ Breast Cancer: A Systematic Review.
PharmacoEconomics – open. 2(4):359-369 [DOI] 10.1007/s41669-018-0070-7. [PMID] 29470807.
2017
Comparison of health utility weights among elderly patients receiving breast-conserving surgery plus hormonal therapy with or without radiotherapy.
Current medical research and opinion. 33(2):391-400 [DOI] 10.1080/03007995.2016.1257983. [PMID] 27819160.
2017
Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives.
Breast cancer research and treatment. 166(3):951-963 [DOI] 10.1007/s10549-017-4473-4. [PMID] 28840424.
2016
Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States.
Breast cancer research and treatment. 160(1):187-196 [PMID] 27654970.
2016
ELICIT: An alternative imprecise weight elicitation technique for use in multi-criteria decision analysis for healthcare.
Expert review of pharmacoeconomics & outcomes research. 16(1):141-7 [DOI] 10.1586/14737167.2015.1083863. [PMID] 26361235.
2016
Parameterization of a disease progression simulation model for sequentially treated metastatic human epidermal growth factor receptor 2 positive breast cancer patients.
Current medical research and opinion. 32(6):991-6 [DOI] 10.1185/03007995.2016.1149056. [PMID] 26824145.
2016
Preventing Unnecessary Costs of Drug-Induced Hypoglycemia in Older Adults with Type 2 Diabetes in the United States and Canada.
PloS one. 11(9) [DOI] 10.1371/journal.pone.0162951. [PMID] 27648831.
2015
A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer.
Breast cancer research and treatment. 151(1):27-40 [DOI] 10.1007/s10549-015-3383-6. [PMID] 25893588.
2015
Application of multicriteria decision analysis in health care: a systematic review and bibliometric analysis.
Health expectations : an international journal of public participation in health care and health policy. 18(6):1894-905 [DOI] 10.1111/hex.12287. [PMID] 25327341.
2015
Improving Health Care Decision Making in the USA Through Comparative Effectiveness Research: The Role of Economic Evaluation
Pharmaceutical Medicine. 29(5):247-253 [DOI] 10.1007/s40290-015-0113-7.
2015
Multi-criteria decision analysis for health technology assessment in Canada: insights from an expert panel discussion.
Expert review of pharmacoeconomics & outcomes research. 15(1):13-9 [DOI] 10.1586/14737167.2015.965155. [PMID] 25267699.
2015
Multicriteria decision analysis in oncology.
Health expectations : an international journal of public participation in health care and health policy. 18(6):1812-26 [DOI] 10.1111/hex.12178. [PMID] 24635949.
2015
Sedative-hypnotic medicines and falls in community-dwelling older adults: a cost-effectiveness (decision-tree) analysis from a US Medicare perspective.
Drugs & aging. 32(4):305-14 [DOI] 10.1007/s40266-015-0251-3. [PMID] 25825121.
2014
Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer.
Breast cancer research and treatment. 147(2):433-41 [DOI] 10.1007/s10549-014-3042-3. [PMID] 25012857.
2014
How to use multi-criteria decision analysis methods for reimbursement decision-making in healthcare: a step-by-step guide.
Expert review of pharmacoeconomics & outcomes research. 14(1):81-99 [DOI] 10.1586/14737167.2014.859525. [PMID] 24328890.
2014
Re: Xie J, Diener M, De G, et al. Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States. J Med Econ 2014;16(2):278-88.
Journal of medical economics. 17(4):248-9 [DOI] 10.3111/13696998.2014.892883. [PMID] 24506762.
2014
Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorial.
PharmacoEconomics. 32(2):101-8 [DOI] 10.1007/s40273-013-0123-9. [PMID] 24338265.
2014
Using quality-adjusted progression-free survival as an outcome measure to assess the benefits of cancer drugs in randomized-controlled trials: case of the BOLERO-2 trial.
Breast cancer research and treatment. 146(3):669-73 [DOI] 10.1007/s10549-014-3047-y. [PMID] 25017612.
2013
Exploring the state of pharmacy profession: The perspective of Côte d’Ivoire
Currents in Pharmacy Teaching and Learning. 5(5):470-476 [DOI] 10.1016/j.cptl.2013.06.005.
2013
Introduction to health economics and decision-making: Is economics relevant for the frontline clinician?
Best practice & research. Clinical gastroenterology. 27(6):831-44 [DOI] 10.1016/j.bpg.2013.08.016. [PMID] 24182604.
2013
Multi-criteria decision analysis (MCDA) in health care: a bibliometric analysis
Operational Research. 2(1):20-24 [DOI] 10.1016/j.orhc.2013.03.001.
2013
Which criteria are considered in healthcare decisions? Insights from an international survey of policy and clinical decision makers.
International journal of technology assessment in health care. 29(4):456-65 [DOI] 10.1017/S0266462313000573. [PMID] 24290340.
2011
A Proposed Framework for Formulary Listing in Low-Income Countries
Pharmaceutical Medicine. 25(2):71-82 [DOI] 10.1007/BF03256848.
2011
An application of a proposed framework for formulary listing in low-income countries: the case of Côte d’Ivoire.
Applied health economics and health policy. 9(6):389-402 [DOI] 10.2165/11595220-000000000-00000. [PMID] 22017499.
2011
Eliciting preferences for reimbursed drugs selection criteria in Côte d’Ivoire.
The patient. 4(2):125-31 [DOI] 10.2165/11586060-000000000-00000. [PMID] 21766901.
2007
Economic impact of Tibolone compared with Continuous-Combined Hormone Replacement Therapy in the management of climacteric symptoms in postmenopausal women.
Maturitas. 58(2):138-49 [PMID] 17870259.

Grants

Mar 2021 – Jun 2021
Incorporating Health Equity into Value Assessment: Frameworks, Promising Alternatives, and Future Directions
Role: Principal Investigator
Funding: PHARMA RES AND MANUFACTURERS OF AMERICA
Jan 2021 – Jun 2021
Racial and Ethnic Disparities in Medication Utilization and Adherence
Role: Principal Investigator
Funding: PHARMA RES AND MANUFACTURERS OF AMERICA
Jan 2020 – Dec 2020
ECONOMIC EVALUATION OF RAPID WHOLE GENOME SEQUENCING (rWGS) IN CRITICALLY ILL CHILDREN AND ADOLESCENTS: THE CASE OF THE NICKLAUS CHILDRENS HOSPITAL
Role: Principal Investigator
Funding: VARIETY CHILDRENS HOSP DBA NICKLAUS
Sep 2016 – Sep 2022
Southeastern and Coastal Center for Agricultural Health and Safety (SCC-AHS)
Role: Project Manager
Funding: CTRS FOR DIS CNTRL INST OCCUP SFTY HLTH

Contact Details

Phones:
Business:
(352) 273-6268
Emails:
Business:
v.diaby@ufl.edu
Addresses:
Business Mailing:
PO Box 100496
GAINESVILLE FL 32610
Business Street:
PO Box 100496
GAINESVILLE FL 32610